Eiger BioPharmaceuticals, Inc. (EIGRQ)

USD 8.5

(6.25%)

Market Cap (In USD)

12.58 Million

Revenue (In USD)

15.77 Million

Net Income (In USD)

-74.96 Million

Avg. Volume

13.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.1-16.0
PE
-
EPS
-
Beta Value
2.776
ISIN
US28249U2042
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Apelian M.B.A., M.D., Ph.D.
Employee Count
-
Website
https://www.eigerbio.com
Ipo Date
2014-01-30
Details
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.